Relation of multiple sclerosis and interferon-beta consumptionwith expression of thioredoxin Trx 1

Regarding the increasing incidence of multiple sclerosis (MS), importance of biomarkers, and also the probable changes in expression of Trx1 gene in this disease, herein we investigated mRNA expression level of Trx1 gene in peripheral blood leukocytes of patients with MS, receiving no medications and those receiving .interferon beta, relative to healthy individuals
Six healthy subjects, as control, and 12 patients with multiple sclerosis, divided into two groups of patients without medications (n=6) and interferon-beta receiving patients (n=6), were included in the study. The numbers of Trx1 mRNA transcripts in two groups of the patients was measured by SYBR green real-time PCR .technique, and compared relative to those of healthy individuals
The mRNA expression of Trx1 in patients without medications was about 1.98 folds higher relative to the healthy controls. However, this difference was not statistically significant (p > 0.05). Also, the mRNA expression of Trx1 in interferon-beta receiving patients exhibited an insignificant increase (p > 0.05) relative to that of healthy .(controls and patients without medications (3.28 and 1.66 folds, respectively
According to our results, the expression of Trx1 gene seems to be a suitable index for MS especially in the patients receiving interferon beta. However, more remains to be elucidated in support of this hypothesis through large-sample size studies. Also, the possible effect of other medications followed by MS patients including .immunosuppressive drugs is suggested to receive attention in future investigations